Similar articles

• The use of lipid-lowering agents in HIV-infected patients.

  Meienberg F, Battegay E, Bucher HC, Battegay M. Meienberg F, et al. J HIV Ther. 2001 May;6(2):40-4. J HIV Ther. 2001. PMID: 11501203 Review. No abstract available.
• Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.

  Bonnet F, Balestre E, Thiébaut R, Mercié P, Dupon M, Morlat P, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Bonnet F, et al. HIV Med. 2004 May;5(3):133-9. doi: 10.1111/j.1468-1293.2004.00200.x. HIV Med. 2004. PMID: 15139977
• Side effects and complications. Extended-release high-dose niacin helps lower lipid levels.

  [No authors listed] [No authors listed] TreatmentUpdate. 2005 Dec;17(7):7-8. TreatmentUpdate. 2005. PMID: 17225322 No abstract available.
• Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.

  Visnegarwala F, Maldonado M, Sajja P, Minihan JL, Rodriguez-Barradas MC, Ong O, Lahart CJ, Hasan MQ, Balasubramanyam A, White AC Jr. Visnegarwala F, et al. J Infect. 2004 Nov;49(4):283-90. doi: 10.1016/j.jinf.2003.09.006. J Infect. 2004. PMID: 15474625
• Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.

  Martínez E, Tuset M, Milinkovic A, Miró JM, Gatell JM. Martínez E, et al. Antivir Ther. 2004 Oct;9(5):649-63. Antivir Ther. 2004. PMID: 15535403 Review.